Eswatini

Continuing the battle against tuberculosis and HIV

An MSF Lab technologist prepares sputum samples at the National TB Reference Laboratory in Mbabane, Eswatini.
ESWATINI 2016 © Alexis Huguet
Click to hide Text

This information is excerpted from MSF’s 2017 International Activity Report.

In 2017, Doctors Without Borders/Médecins Sans Frontières (MSF) continued to focus on reducing HIV transmission and improving access to decentralized care for people with HIV, tuberculosis (TB) and drug-resistant TB (DR-TB).

Eswatini, previously known as Swaziland, has one of the world’s highest rates of HIV, affecting roughly one in three adults. The HIV epidemic is showing signs of stabilizing and in recent years the number of AIDS-related deaths has reduced. Based on a 2017 HIV incidence survey, the rate of new infections has almost halved within five years.

In Shiselweni region, MSF continued with its ‘test and treat’ strategy, providing immediate treatment at the time of HIV diagnosis, irrespective of clinical criteria. In addition, MSF introduced innovative approaches such as pre-exposure prophylaxis (PrEP) for patients at increased risk of HIV infection, and oral HIV self-testing for hard-to-reach people. A total of 129 patients initiated PrEP and 2,140 people have accessed HIV self-testing since May.

MSF is increasingly focused on providing specialized care and support for people living with HIV. This includes providing second- and third-line antiretroviral (ARV) treatment, cervical cancer screening, and routine point-of-care screening for the cryptococcal antigen, an indicator of meningitis. In 2017, 2,637 women were screened for cervical cancer, 17 percent of whom tested positive. Of these, 60 percent were treated. MSF also provides community-based HIV care, including treatment clubs for adults and children.

Eswatini has one of the highest Tuberculosis (TB) notification rates worldwide. Because of the close connection between the HIV and TB epidemics, 70 percent of people who contract TB are also HIV positive.

In Manzini region, MSF continued its research into the shorter-course treatment for multidrug-resistant TB (MDR-TB). A total of 149 patients were enrolled in the study; 132 patients finished their treatment, with a cure rate of 72 percent. The study will be concluded in 2018 when the one-year follow-up is finalized. Since 2017, the shorter DR-TB regimen has been included in the national protocol, with MSF providing technical support for its implementation. MSF continued to offer technical support to the national TB reference laboratory in Mbabane and helped to upgrade the Biosafety level 3 laboratory.

The national TB program has made significant progress with regards to provision and use of new TB drugs, diagnostics, and decentralization of treatment and care. It also started taking over the provision of support packages for DR-TB patients. These include nutrition and treatment support, as well as transport costs, which help improve patients’ adherence to their regimen.

Due to the decreased incidences of HIV and TB, the resulting lower illness and mortality rates, and improvements in the Ministry of Health’s capacity to manage the diseases, MSF has decided to gradually hand over its projects in Manzini. In March, MSF handed over most of its services at Matsapha comprehensive health care clinic to AIDS Healthcare Foundation, while continuing to support the DR-TB program and the laboratory. In December, DR-TB activities in Mankayane hospital and Luyengo clinic were handed over to the Ministry of Health.